Tvardi Therapeutics (NASDAQ:TVRD) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD - Free Report) in a research note issued to investors on Friday, MarketBeat reports. The brokerage issued an overweight rating and a $52.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Tvardi Therapeutics' FY2025 earnings at ($2.19) EPS.

TVRD has been the subject of a number of other reports. Oppenheimer began coverage on Tvardi Therapeutics in a research report on Wednesday, May 21st. They issued an "outperform" rating and a $65.00 target price for the company. Wall Street Zen upgraded Tvardi Therapeutics to a "hold" rating in a research note on Saturday, May 24th. Finally, Piper Sandler initiated coverage on Tvardi Therapeutics in a research note on Thursday, June 12th. They issued an "overweight" rating and a $78.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $64.25.

Tvardi Therapeutics Stock Up 9.1%

Tvardi Therapeutics stock traded up $2.49 during midday trading on Friday, reaching $29.83. The stock had a trading volume of 72,682 shares, compared to its average volume of 34,595. Tvardi Therapeutics has a 12 month low of $8.13 and a 12 month high of $34.31.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.